Incannex Healthcare Announces Commencement of IHL-42X Phase 2 Dosing and U.S. Patent Grant

Filing content

Incannex Healthcare reported the start of patient dosing in its Phase 2 study of IHL-42X, the grant of a U.S. composition patent, and a cash position of approximately $70 million with no debt.